Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level differences.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET).

ESMO open·2025

Same author

Impact of universal use of the McGrath videolaryngoscope as the first option for all intubations in the operating room: The multicentre prospective before-after VIDEOLAR-SURGERY study protocol.

Revista espanola de anestesiologia y reanimacion..·2024

Same author

Exploring tear viscosity with quartz crystal microbalance technology.

The Review of scientific instruments·2024

Same author

Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study.

Journal of endocrinological investigation·2024

Same author

A Review of the EUSO-Balloon Pathfinder for the JEM-EUSO Program.

Space science reviews·2022

Same journal

Deconvoluting MLL1-dependent pathways in hematopoiesis and leukemogenesis.

Leukemia supplements·2016

Same journal

New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance.

Leukemia supplements·2016

Same journal

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

Leukemia supplements·2016

Same journal

Dissecting reprogramming, differentiation and conversion with network biology.

Leukemia supplements·2016

Same journal

Insights into the pathophysiology and therapy of myeloproliferative neoplasms from mouse models.

Leukemia supplements·2016

Same journal

Myeloid differentiation and the leukemia-initiating cell.

Leukemia supplements·2016

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Minimal residual disease.

D Campana¹

¹Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Centre for Translational Medicine , Singapore, Singapore.

Leukemia Supplements

|May 14, 2016

Summary

This summary is machine-generated.

Minimal residual disease (MRD) monitoring in acute leukemia accurately measures treatment response and detects relapse early. This prognostic indicator is crucial for guiding risk-adapted therapy and improving patient management.

Keywords:

PCR acute lymphoblastic leukemia acute myeloid leukemia flow cytometry minimal residual disease

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Related Experiment Videos

Last Updated: Mar 21, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Area of Science:

Hematology
Oncology
Clinical Pathology

Background:

Minimal residual disease (MRD) monitoring is vital in acute leukemia management.
Accurate assessment of residual leukemic burden impacts clinical decisions.

Purpose of the Study:

To review the current status of MRD detection in acute leukemia.
To highlight the importance of MRD in treatment response assessment and relapse detection.

Main Methods:

Flow cytometry and polymerase chain reaction (PCR) are key methods for MRD detection.
These techniques have been applied to numerous patients with acute lymphoblastic leukemia and acute myeloid leukemia.

Main Results:

MRD monitoring provides accurate initial treatment response measurement.
It allows for assessment of residual leukemic burden throughout therapy.
MRD detection enables early identification of relapse.

Conclusions:

Minimal residual disease is a powerful prognostic indicator in acute leukemia.
MRD monitoring is indispensable for risk-adapted therapy.
Information from MRD studies significantly improves clinical management.